Nociceptive Pain is an indication for drug development with over 190 pipeline drugs currently active. According to GlobalData, preregistered drugs for Nociceptive Pain have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Nociceptive Pain compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nociceptive Pain overview
Nociceptive pain is a type of pain caused by the stimulation of specialized sensory nerve fibers called nociceptors in response to tissue damage or injury. It’s a protective mechanism signaling potential harm, typically arising from cuts, burns, fractures, or inflammation. Nociceptive pain is often described as sharp, aching, or throbbing and is localized to the affected area. It serves as an important warning signal, prompting individuals to protect the injured area. Treatments for nociceptive pain focus on addressing the underlying cause and often involve medications like nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, rest, and interventions targeted at healing the injury or tissue damage.
For a complete picture of PTSR and LoA scores for drugs in Nociceptive Pain, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
